These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 7533400)
1. Endothelial expression of human decay accelerating factor in transgenic pig tissue: a potential approach for human complement inactivation in discordant xenografts. Rosengard AM; Cary N; Horsley J; Belcher C; Langford G; Cozzi E; Wallwork J; White DJ Transplant Proc; 1995 Feb; 27(1):326-7. PubMed ID: 7533400 [No Abstract] [Full Text] [Related]
2. Expression of human decay accelerating factor in transgenic pigs. Cozzi E; Langford GA; Richards A; Elsome K; Lancaster R; Chen P; Yannoutsos N; White DJ Transplant Proc; 1994 Jun; 26(3):1402-3. PubMed ID: 7518135 [No Abstract] [Full Text] [Related]
3. Production of pigs transgenic for human decay accelerating factor. Langford GA; Yannoutsos N; Cozzi E; Lancaster R; Elsome K; Chen P; Richards A; White DJ Transplant Proc; 1994 Jun; 26(3):1400-1. PubMed ID: 7518134 [No Abstract] [Full Text] [Related]
4. Expression of human DAF and MCP on pig endothelial cells protects from human complement. Carrington CA; Richards AC; Cozzi E; Langford G; Yannoutsos N; White DJ Transplant Proc; 1995 Feb; 27(1):321-3. PubMed ID: 7533398 [No Abstract] [Full Text] [Related]
5. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. McCurry KR; Kooyman DL; Diamond LE; Byrne GW; Logan JS; Platt JL Transplantation; 1995 Apr; 59(8):1177-82. PubMed ID: 7537395 [TBL] [Abstract][Full Text] [Related]
6. Permanent expression of human CD59 and/or decay-accelerating factor by rat endothelial cells confers protection from human complement-mediated lysis. Charreau B; Cassard A; Tesson L; Le Mauff B; Blanchard D; Lublin D; Soulillou JP; Anegon I Transplant Proc; 1995 Feb; 27(1):336-7. PubMed ID: 7533404 [No Abstract] [Full Text] [Related]
8. High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Oldham ER; Velardo MA; Platt JL; Logan JS; Diamond L Transplant Proc; 1996 Apr; 28(2):693. PubMed ID: 8623349 [No Abstract] [Full Text] [Related]
9. Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55). Miyagawa S; Shirakura R; Nakata S; Izutani H; Matsuda H; Iwata K; Nagasawa S; Terado A; Hatanaka M; Matsumoto M Transplant Proc; 1995 Feb; 27(1):328-9. PubMed ID: 7533401 [No Abstract] [Full Text] [Related]
10. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. Rosengard AM; Cary NR; Langford GA; Tucker AW; Wallwork J; White DJ Transplantation; 1995 May; 59(9):1325-33. PubMed ID: 7539168 [TBL] [Abstract][Full Text] [Related]
11. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Cary N; Moody J; Yannoutsos N; Wallwork J; White D Transplant Proc; 1993 Feb; 25(1 Pt 1):400-1. PubMed ID: 7679815 [No Abstract] [Full Text] [Related]
12. Comparative analysis of human DAF expression in the tissues of transgenic pigs and man. Cozzi E; Langford GA; Wright L; Tucker A; Yannoutsos N; Richards A; Rosengard A; Elsome K; Lancaster R; White DJ Transplant Proc; 1995 Feb; 27(1):319-20. PubMed ID: 7533397 [No Abstract] [Full Text] [Related]
13. Evidence that double transfection to xenoendothelial cells using GPI-anchoring complement regulatory factor (decay-accelerating factor and homologous restriction factor 20) gene is useful for the inhibition of human complement-mediated cytolysis. Hayashi S; Isobe K; Emi N; Okada H; Yasutomi M; Negita M; Koike C; Uchida K; Yokoyama I; Takagi H Transplant Proc; 1995 Feb; 27(1):330. PubMed ID: 7533402 [No Abstract] [Full Text] [Related]
17. Production of pigs transgenic for human regulators of complement activation. Yannoutsos N; Langford GA; Cozzi E; Lancaster R; Elsome K; Chen P; White DJ Transplant Proc; 1995 Feb; 27(1):324-5. PubMed ID: 7533399 [No Abstract] [Full Text] [Related]
18. Characterization of complement-mediated liver damage and protection in control and transgenic mice for human complement blockers MCP and DAF. Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Marinucci G; Melli CM; Bruzzone P; Alfani D; Cortesini R; Rossini M Transplant Proc; 1996 Feb; 28(1):127-9. PubMed ID: 8644143 [No Abstract] [Full Text] [Related]
19. Human MCP and DHF double transgenic mice are protected from human complement attack in an in vivo model. Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Melli C; Bruzzone P; Alfani D Transplant Proc; 1996 Apr; 28(2):589. PubMed ID: 8623287 [No Abstract] [Full Text] [Related]
20. Inhibition of species-specific complement-mediated cytolysis in xenoendothelial cells transfected with GPI-anchored complement regulatory factor (DAF, HRF20) gene using retroviral vector: comparison between single (DAF or HRF20) and double (DAF and HRF20) transfected xenoendothelial cells. Hayashi S; Isobe K; Emi N; Yokoyama I; Takagi H Transplant Proc; 1994 Jun; 26(3):1243-4. PubMed ID: 7518119 [No Abstract] [Full Text] [Related] [Next] [New Search]